Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1986-12-5
|
| pubmed:abstractText |
This investigation was performed in two groups of adult patients, 10 with type I and 10 with type II diabetes mellitus, all with arterial hypertension (160 to 200 mm Hg systolic and 95 to 120 mm Hg diastolic). Captopril, 50 mg twice a day, was administered for 12 weeks and was effective as monotherapy in 16 patients. Mean arterial pressure (+/- s.d.) in type I patients changed from 121.4 +/- 9.6 to 100.2 +/- 10.1 after 4 weeks and to 102.0 +/- 3.8 mm Hg after 12 weeks; in type II patients it changed from 132.8 +/- 5.7 to 123.9 +/- 13.5 after 4 weeks and to 109.1 +/- 11.1 mm Hg after 12 weeks. The differences were statistically significant. In only 4 patients was it necessary to add a thiazide after the first month of therapy. No significant change was induced by captopril in urine output, osmolar clearance, free water clearance inulin, and PAH clearances. No significant change was observed in serum and urine Na+, Cl-, Ca++ and Mg++, whereas a statistically significant reduction was found in the renal clearances of K+ and PO4-. No important change in serum aldosterone was found, while plasma renin activity was increased, as expected. No alterations in urine protein, glucosaminoglycans, gamma GT, and N-acetyl-beta-glucosaminidase were observed during follow-up. All patients maintained good metabolic control of their disease. No neutropenia and orthostatic hypotension were seen. Captopril appears to be an effective and safe drug for lowering blood pressure in diabetic patients, without affecting renal function, electrolyte balance and the metabolic control of diabetes.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0032-5473
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
62 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
69-72
|
| pubmed:dateRevised |
2009-10-22
|
| pubmed:meshHeading |
pubmed-meshheading:3534866-Adult,
pubmed-meshheading:3534866-Blood Pressure,
pubmed-meshheading:3534866-Captopril,
pubmed-meshheading:3534866-Carbohydrate Metabolism,
pubmed-meshheading:3534866-Diabetes Mellitus, Type 1,
pubmed-meshheading:3534866-Diabetes Mellitus, Type 2,
pubmed-meshheading:3534866-Electrolytes,
pubmed-meshheading:3534866-Female,
pubmed-meshheading:3534866-Humans,
pubmed-meshheading:3534866-Hypertension,
pubmed-meshheading:3534866-Male,
pubmed-meshheading:3534866-Middle Aged
|
| pubmed:year |
1986
|
| pubmed:articleTitle |
Captopril in the treatment of hypertension in type I and type II diabetic patients.
|
| pubmed:publicationType |
Journal Article
|